Lemborexant-induced interstitial lung disease: A case report.
Satoshi Nakahara1, Yumiko Ishii1, Reika Egashira1
1Department of Respiratory Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
Lemborexant, a medication for insomnia, can cause drug-induced interstitial lung disease. A patient experienced acute respiratory symptoms and lung opacity after taking lemborexant, with a positive diagnostic test and rapid improvement after steroid treatment.
Area of Science:
- Pulmonology
- Pharmacology
- Internal Medicine
Background:
- Insomnia is a common sleep disorder affecting millions globally.
- Lemborexant is a dual orexin receptor antagonist prescribed for insomnia.
- Drug-induced interstitial lung disease (DIILD) is a rare but serious adverse reaction to medications.
More Related Videos
09:58Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS
Published on: April 18, 2018
06:03Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
Related Concept Videos
Pleural Effusion I: Introduction
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
Pulmonary Embolism I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Pulmonary Embolism I: Introduction
